Plain-English translation of NCT05783804 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether young adults with familial hypercholesterolemia—a genetic condition that causes very high cholesterol—can actually reverse the plaque buildup in their heart arteries by starting intensive cholesterol-lowering medication early. Researchers want to know if aggressive treatment can shrink existing plaque, not just prevent it from getting worse. This is important because it could change how doctors treat young people at high risk for heart disease.
Most heart disease treatments focus on stopping plaque from growing, but doctors don't know yet whether this medication can actually make existing plaque smaller in younger patients. This trial aims to answer that question and could help prevent heart attacks in people with genetic high cholesterol.
You likely qualify if…
You likely don't qualify if…
Participants will take intensive cholesterol-lowering medication as prescribed and attend study visits where doctors will monitor their cholesterol levels and heart health. The study will likely include imaging tests (such as ultrasound or scans) to measure whether plaque in the arteries has changed. You would be expected to follow the treatment plan closely and attend all scheduled appointments over the course of the study.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Netherlands
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment target
~60 participants
Started
July 2022
Primary completion
December 2026
Age range
18 Years – 50 Years
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Erik SG Stroes, MD, PhD
Amsterdam UMC, location AMC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.